Stockscreener 앱 받기
47.69
0.02%
-0.01
시간 외 거래:
47.67
-0.02
-0.04%
Tourmaline Bio Inc 주식(TRML)의 최신 뉴스
How to contact the Daily Bulletin - FinancialContent
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML) - Eastern Progress
26,000 Shares in Tourmaline Bio, Inc. $TRML Purchased by Wesbanco Bank Inc. - MarketBeat
Fed Meeting: What is the next catalyst for Tourmaline Bio IncInsider Buying & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Quarterly Earnings: Is Tourmaline Bio Inc. stock a good dividend stockGold Moves & Free Expert Verified Stock Movement Alerts - خودرو بانک
RSI Check: Does Tourmaline Bio Inc stock have upside surprise potentialJuly 2025 Levels & Real-Time Volume Spike Alerts - خودرو بانک
Tourmaline Bio (NASDAQ:TRML) Reaches New 12-Month HighHere's Why - MarketBeat
Big Picture: Is Tourmaline Bio Inc. gaining market shareJuly 2025 Spike Watch & Risk Controlled Swing Trade Alerts - خودرو بانک
Market Pulse: What are AA Mission Acquisition Corps technical support levelsSell Signal & Daily Profit Maximizing Trade Tips - خودرو بانک
Tourmaline Bio (NASDAQ:TRML) Downgraded by BMO Capital Markets to Market Perform - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Cut to Neutral at Chardan Capital - MarketBeat
Guggenheim Reaffirms "Neutral" Rating for Tourmaline Bio (NASDAQ:TRML) - MarketBeat
Setup Watch: Whats Tourmaline Bio Incs historical returnWeekly Trade Summary & Weekly Sector Rotation Insights - خودرو بانک
Institution Moves: Is Tourmaline Bio Inc a cyclical or defensive stockWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - خودرو بانک
Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition - ca.finance.yahoo.com
BMO Capital Downgrades Tourmaline Bio to Market Perform From Outperform, Raises Price Target to $48 From $35 - MarketScreener
This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday - Benzinga
BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news - Investing.com Canada
905,000 Shares in Tourmaline Bio, Inc. $TRML Acquired by Octagon Capital Advisors LP - MarketBeat
Novartis to Buy US Biotech Tourmaline Bio for $1.4 Billion - MSN
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpShould You Buy? - MarketBeat
Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows - uk.finance.yahoo.com
Tourmaline Bio (NASDAQ:TRML) Cut to Hold at Lifesci Capital - MarketBeat
Tourmaline Bio Updates Executive Severance Plan - MSN
Tourmaline Bio (NASDAQ:TRML) Lowered to "Hold" Rating by Piper Sandler - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week HighWhat's Next? - MarketBeat
Tourmaline Bio stock hits 52-week high at 47.69 USD - Investing.com India
Why Tourmaline Bio Inc. stock could outperform in 20252025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Tourmaline Bio stock hits 52-week high at 47.69 USD By Investing.com - Investing.com Australia
Tourmaline Bio (NASDAQ:TRML) Sees Strong Trading VolumeHere's What Happened - MarketBeat
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline - MSN
Tourmaline Bio (NASDAQ:TRML) Stock Rating Lowered by Truist Financial - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Lowered to "Neutral" Rating by HC Wainwright - MarketBeat
Tourmaline Bio, Inc. $TRML Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
American Century Companies Inc. Raises Stake in Tourmaline Bio, Inc. $TRML - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novartis to Buy Tourmaline Bio for $48 Per Share in Cash - MSN
Tourmaline Bio (NASDAQ:TRML) Cut to "Hold" at Jefferies Financial Group - MarketBeat
Novartis adds late-stage anti-inflammatory asset with $1.4 billion Tourmaline Bio acquisition - DOTmed
Biotech Stocks To ConsiderSeptember 9th - MarketBeat
Tourmaline Bio Merges with Novartis for $1.4 Billion - MSN
Hsbc Holdings PLC Acquires Shares of 10,357 Tourmaline Bio, Inc. $TRML - MarketBeat
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - FinancialContent
Piper Sandler Downgrades Tourmaline Bio to Neutral From Overweight, Lowers Price Target to $48 From $65 - MarketScreener
Tourmaline Bio (NASDAQ:TRML) Stock Rating Lowered by Wedbush - MarketBeat
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Novartis Acquires Tourmaline Bio for $1.4 Billion | - openPR.com
Novartis Acquires Tourmaline Bio for $1.4 Billion | DelveInsight’s Perspective on ASCVD Market Impact, Competitive Landscape and Anti-Inflammatory Pipeline Expansion - Barchart.com
Best Medical Stocks Worth WatchingSeptember 9th - MarketBeat
0.25%
0.14%
자본화:
|
볼륨(24시간):